Alemtuzumab in Covid era

BACKGROUND: The SARS-CoV-2 pandemic impact on people with Multiple Sclerosis (pwMS) continues to worry. The disease modifying therapies in pwMS can add a more severe risk of infection when compared to the general population. Alemtuzumab is an anti-CD52 monoclonal antibody and it is one of the most i...

Descripción completa

Detalles Bibliográficos
Autores principales: Iovino, Aniello, Olivieri, Nunzio, Aruta, Francesco, Giaquinto, Emanuele, Ruggiero, Lucia, Spina, Emanuele, Tozza, Stefano, Manganelli, Fiore, Iodice, Rosa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969858/
https://www.ncbi.nlm.nih.gov/pubmed/33812222
http://dx.doi.org/10.1016/j.msard.2021.102908

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969858/
https://www.ncbi.nlm.nih.gov/pubmed/33812222
http://dx.doi.org/10.1016/j.msard.2021.102908

Ejemplares similares